Brief Reports Open Access
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 15, 2003; 9(7): 1607-1610
Published online Jul 15, 2003. doi: 10.3748/wjg.v9.i7.1607
Effect of P-selectin monoclonal antibody on metastasis of gastric cancer and immune function
Jin-Lian Chen, Wei-Xiong Chen, Jin-Shui Zhu, Ni-Wei Chen, Department of Gastroenterology, Shanghai Jiao-Tong University affiliated Sixth People’s Hospital, Shanghai 200233, China
Tong Zhou, Yun-Lin Wu, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China
Ming Yao, Shanghai Cancer Institute, Shanghai 200233, China
Dong-Qing Zhang, Shanghai Institute of Immunology, Shanghai 200025, China
Author contributions: All authors contributed equally to the work.
Supported by the Youth Science Foundation of Shanghai Public AdministrationNo.131984Y15
Correspondence to: Jin-Lian Chen, Department of Gastroenterology, Shanghai Sixth People’s Hospital, Shanghai Jiao-Tong University affiliated Sixth People’s Hospital, Shanghai 200233, China. wqq_021002@163.com
Telephone: +86-21-64369181
Received: March 2, 2003
Revised: March 14, 2003
Accepted: March 29, 2003
Published online: July 15, 2003

Abstract

AIM: To investigate the effect of cell adhesion molecule P-selectin monoclonal antibody (Mab) on metastasis and immune function of mice orthototopically implanted with human gastric cancer tissue.

METHODS: SCID mice were implanted orthotopically with SGC-7901 human gastric carcinoma tissue. Starting from day 3 after operation, animals were given intravenously PBS or P-selectin Mab (100 μg/injection) (for both normal mice and tumor-implanted mice with tumors), twice weekly for 3 wk. Two animals in each group were sacrificed randomly at the 1st, 2nd, 4th week and 6th week. While T cell and B cell transformation indices were determined with the 3H TdR infiltration method, the NK cell activity was detected by the LDH release method.

RESULTS: The metastatic rate in the P-selectin Mab treated group was lower than that in the PBS treated group (with tumors). The NK activity of normal mice increased over time. The immune functions (T, B cell function, NK activity) of the tumor group in the 6th week were significantly lower than those in the 4th week, but the change was attenuated by P-selectin Mab.

CONCLUSION: P-selectin Mab could suppress the metastasis of gastric cancer with no adverse effect on host immune function.




INTRODUCTION

Gastric carcinoma is one of the most frequent tumors in China. Tumor metastasis is very common clinically. Cell adhesion molecules have been implicated to be crucial elements in the process of metastasis[1-28]. P-selectin is an adhesion molecules that mediates the cell to cell interaction of platelets and endothelial cells with neutrophils and monocytes as well as tumor cells[29]. Our previous study indicates that P-selectin expression is related to aggressive behavior, dissemination and poor prognosis of human gastric carcinomas, and P-selectin monoclonal artibody can inhibit gastric carcinoma metastasis[30-32]. The present study was performed to investigate effects of P-selectin monoclonal antibody on metastasis and immune function in SCID mouse metastaic models of human gastric cancer constructed by orthotopic implantation of histologically intact tumor tissue.

MATERIALS AND METHODS
Animal model

Forty-eight male SCID mice obtained from Shanghai Cancer Institute were 7-8 wk old with weight of 20-25 g. Human gastric cancer SGC-7901, a poorly-differentiated adenocarcinoma line, was originally derived from a primary tumor and maintained by passage in nude mice subcutaneously.

SCID mice were randomly divided into experimental group (n = 24) and normal group (n = 24). Animal models in experimental group were made using orthotopic implantation of histologically intact tissue of human gastric carcinoma[33]. Tumors were resected aseptically. Necrotic tumor tissues were removed and the remaining non-necrotic tumor tissues were minced into pieces about 5-7 mm in diameter in Hank’s balanced salt solution. Each of the tumor pieces was weighed and adjusted to be 150 mg with scissors. Mice were anesthetized with 4.3% trichloraldehyde hydrate and an incision was made through the left upper abdominal pararectal line and peritoneal cavity was carefully exposed and a part of the serosal membrane in the middle of the greater curvature of the glandular stomach was mechanically injured by using scissors. A tumor piece of 150 mg was fixed on each injured site of the serosal surface. The stomach was then returned to the peritoneal cavity, and the abdominal wall and skin were closed. 3 d later, all animals implanted with intact tumor tissues received i.v. injection of PBS (group3, n = 12) or P-selectin antibody (Suzhou Medical College; 100 μg/injectiom; group4, n = 12) twice weekly for 3 wk. Animals in normal group received i.v. injections of PBS (group1, n = 12) or P-selectin antibody (100 μg/injection; group2, n = 12).

Sample collection and pathological examination

Two mice in each group were sacrificed randomly on weeks 1, 2, and 4. The remaining animals were sacrificed at 6th week and the tumors growing on the stomach wall were removed and examined histologically. Tissues from all organs were examined for metastasis after careful macroscopic examination. The spleen of mice was harvested for detection of immune function.

Lymphocyte transformation test

Using 3H TdR infiltration method, T cell transformation function was detected with Con A (5 μg/ml, Sigma), B cell function with LPS (50 μg/ml, Sigma). The spleen was made into suspension and mononuclear cells were acquired with lymphocyte-separating fluid. The cell suspension was adjusted to 2 × 106/mL with RPMI 1640 liquid containing 10% calf serum (GIBCO). Then 200 μL of the cell suspension was put into each well in 96-well plates. One plate was for Con A group, and another plate for LPS group. There were negative control group and experimental group for Con A or LPS group respectively, and each test had 5 repetitive wells and was cultivated under 5% CO2 at 37 °C. The cell suspension in Con A group was cultivated for 3 d, while it was done for 5 d in Con A group. All wells were added up 3H TdR 16 h before the end of cultivation. They were collected in filtration paper, and given 0.5 mL of scintillating liquid to detect cpm value with β-scintillator, which was presented with SI. SI amounts to cpm of experimental group/cpm of empty group.

NK activity

NK activity was detected by the 4 h LDH release method. NK cell activity (%) = (Experimental group’s OD-Natural release group’s OD)/(Max release group’s OD-Natural release group’s OD)

Statistical methods

Comparisons among groups were performed by the student’s test and χ2 test. A value of P < 0.05 was considered significant.

RESULTS
Effects of P-selectin antibody on metastasis

All animals in each group were sacrificed randomly at the 1st, 2nd, 4th week and 6th week. Tumors grew in the implanted site. Under microscopy, the tumors demonstrated lower differentiated adenocarcinoma invadeing mucosal layer, submucosal layer and muscle layer. Tumor metastasis was observed most frequently in the regional lymph nodes and liver. It could be seen in lung, spleen and other organs.

In tumor group (Group 3), no metastasis was found at the 1st and 2nd week, but metastasis was found in 1 of 2 cases at the 4th week, in 5 of 6 cases at 6th week. However, in P-selectin antibody treated tumor group (Group 4), tumor metastasis was remarkably inhibited. No metastasis was found at 1st, 2nd, and 4th week, while it was found only in 1 of 6 mice at 6th week.

Effect of P-selectin antibody on immune function

The NK activity of normal mice increased over time, but no significant difference of the immune functions of T cell and B cell was found in all the groups. Over time, the immune functions (T, B cell function, NK activity) of SCID mice orthotopically implanted with tumor tissue were significantly lower in the 6th week than those in the 4th week, but the change was attenuated by P-selectin antibody (P < 0.05) (Table 1).

Table 1 Immune functions of mice in various groups (¯x ± s).
GroupWeek 1Week 2Week 4Week 6
T cell transformation indices (SI)
Group 11.95 ± 0.162.19 ± 0.182.28 ± 0.192.35 ± 0.20
Group 22.10 ± 0.192.13 ± 0.212.42 ± 0.232.27 ± 0.22
Group 31.83 ± 0.171.77 ± 0.181.58 ± 0.151.01 ± 0.10d
Group 41.92 ± 0.191.82 ± 0.161.63 ± 0.171.43 ± 0.13a
B cell transformation indices (SI)
Group 12.57 ± 0.222.35 ± 0.232.76 ± 0.242.87 ± 0.26
Group 22.49 ± 0.242.33 ± 0.262.82 ± 0.282.59 ± 0.29
Group 32.54 ± 0.232.48 ± 0.242.20 ± 0.221.49 ± 0.12d
Group 42.60 ± 0.222.51 ± 0.212.43 ± 0.262.11 ± 0.20a
NK activity (90)
Group 18.66 ± 0.7811.21 ± 0.9914.22 ± 1.22b18.62 ± 1.14c
Group 28.96 ± 0.9111.39 ± 1.1213.75 ± 1.0317.99 ± 1.36
Group 38.12 ± 0.817.63 ± 0.746.75 ± 0.624.17 ± 0.52d
Group 48.00 ± 0.737.61 ± 0.836.97 ± 0.626.24 ± 0.63a
DISCUSSION

Research on cell adhesion molecules and metastasis has aroused a lot of attention recently[34-50]. P-selectin (GMP140, CD62, or PADGEM) is located in alpha granules of platelets and Weibel-Palade bodies of endothelial cells. Once platelet or endothelial cell is activated by mediators such as thrombin, alpha granule and weibel-palade body membranes fuse rapidly with the plasma membrane, leading to the expression of P-selectin on the cell surface[29]. P-selectin contributes to interaction of tumor cell to cell adhesion by mediating endothelial cells and platelets with tumor cells.

We have immunohistochemically studied P-selectin expression in 60 cases of human gastric carcinomas. The study showed that P-selectin was expressed in human gastric cancer, which was detected not only on intratumoral endothelium but also on cancer cells. P-selectin expression was found higher in patients with lymph node metastasis than those without metastasis. The survival time and five-year survival rate were lower in P-selectin positive cases than those in negative cases[30-32]. Recently, our study indicated that P-selectin mRNA expression is related to tumor metastasis, and the metastasis may be inhibited by the monoclonal antibody. This finding is in accordance with Stone’s results[22]. These results suggest that selectins play an important role in metastasis by mediating the interaction of endothelial cells and platelets with cancer cells, and the metastasis can be inhibited by the monoclonal antibody.

Recently, study on anti-adhesion therapy with adhesion molecule monoclonal antibodies exhibits good clinical prospective[51-53]. However, there existed some problems. Antibody against intercellular adhesion molecule-1 (ICAM-1) might block inflammation while it inhibits the immune function of the body so that it increases the risk for infection[54,55]. The present study investigated the effects of P-selectin monoclonal antibody on tumor metastasis and immune function of SCID mice orthotopically implanted with gastric cancer tissue to lay foundation for clinical application of anti-adhesion therapy. The result indicated that P-selectin antibody could inhibit the metastasis. This is consistent with our previous study.

Results obtained in this study showed that NK activity of normal mice got higher with the passage of time. It was higher at 6th week than between 1st week and 4th week. But there had no significant change in both T cell and B cell function. The experiment suggested that mice used for metastasis models should not be too old, otherwise the metastasis rate of the mice implanted with tumor would be low. Our experiment discovered that the immune functions (T, B cell function, NK activity) of the tumor group were significantly lower in the 6th week than in the 4th week, but the change was remarkably attenuated by P-selectin antibody. No difference of the immune functions between the two groups at 1st, 2nd, 4th week was found. This result suggested that the immune functions of mice was suppressed with the development of tumor metastasis. On the other hand, the metastatic rates of tumor group were 50% (1/2) at 4th week and 83.3% (5/6) at 6th week, whereas it was 16.7% (1/6) at 6th week in P-selectin antibody treated tumor group. Therefore, the improved immune function in the antibody treated tumor group might result from the inhibition of metastasis by the P-selectin monoclonal antibody. Sharar discovered that P-selectin could not inhibit functions of neutrophils. The results suggest that P-selectin monoclonal antibody could inhibit the metastatic tendency with no harmful effect on host immune function.

Footnotes

Edited by Ren SY

References
1.  Xin Y, Li XL, Wang YP, Zhang SM, Zheng HC, Wu DY, Zhang YC. Relationship between phenotypes of cell-function differentiation and pathobiological behavior of gastric carcinomas. World J Gastroenterol. 2001;7:53-59.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Ikonen T, Matikainen M, Mononen N, Hyytinen ER, Helin HJ, Tommola S, Tammela TL, Pukkala E, Schleutker J, Kallioniemi OP. Association of E-cadherin germ-line alterations with prostate cancer. Clin Cancer Res. 2001;7:3465-3471.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Tsujitani S, Kaibara N. [Clinical significance of molecular biological detection of micrometastases in gastric carcinoma]. Nihon Geka Gakkai Zasshi. 2001;102:741-744.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Murahashi K, Yashiro M, Takenaka C, Matsuoka T, Ohira M, Chung KH. Establishment of a new scirrhous gastric cancer cell line with loss of heterozygosity at E-cadherin locus. Int J Oncol. 2001;19:1029-1033.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 4]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
5.  Okada Y, Fujiwara Y, Yamamoto H, Sugita Y, Yasuda T, Doki Y, Tamura S, Yano M, Shiozaki H, Matsuura N. Genetic detection of lymph node micrometastases in patients with gastric carcinoma by multiple-marker reverse transcriptase-polymerase chain reaction assay. Cancer. 2001;92:2056-2064.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 6]  [Reference Citation Analysis (0)]
6.  Yanagimoto K, Sato Y, Shimoyama Y, Tsuchiya B, Kuwao S, Kameya T. Co-expression of N-cadherin and alpha-fetoprotein in stomach cancer. Pathol Int. 2001;51:612-618.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 13]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
7.  Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ, Donohue JH. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated. Cancer. 2001;92:181-187.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Shun CT, Wu MS, Lin MT, Chang MC, Lin JT, Chuang SM. Immunohistochemical evaluation of cadherin and catenin expression in early gastric carcinomas: correlation with clinicopathologic characteristics and Helicobacter pylori infection. Oncology. 2001;60:339-345.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 22]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
9.  Xin Y, Grace A, Gallagher MM, Curran BT, Leader MB, Kay EW. CD44V6 in gastric carcinoma: a marker of tumor progression. Appl Immunohistochem Mol Morphol. 2001;9:138-142.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 24]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
10.  Chan AO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, Yuen ST, Law SY, Hui WM, Lai KC. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut. 2001;48:808-811.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 64]  [Cited by in F6Publishing: 69]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
11.  Chan JK, Wong CS. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv Anat Pathol. 2001;8:165-172.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 33]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
12.  Werner M, Becker KF, Keller G, Höfler H. Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol. 2001;127:207-216.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 81]  [Cited by in F6Publishing: 95]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
13.  Machado JC, Oliveira C, Carvalho R, Soares P, Berx G, Caldas C, Seruca R, Carneiro F, Sobrinho-Simöes M. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 2001;20:1525-1528.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 193]  [Cited by in F6Publishing: 210]  [Article Influence: 9.1]  [Reference Citation Analysis (0)]
14.  Tamura G, Sato K, Akiyama S, Tsuchiya T, Endoh Y, Usuba O, Kimura W, Nishizuka S, Motoyama T. Molecular characterization of undifferentiated-type gastric carcinoma. Lab Invest. 2001;81:593-598.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 57]  [Cited by in F6Publishing: 58]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
15.  Futamura N, Nakamura S, Tatematsu M, Yamamura Y, Kannagi R, Hirose H. Clinicopathologic significance of sialyl Le(x) expression in advanced gastric carcinoma. Br J Cancer. 2000;83:1681-1687.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 27]  [Cited by in F6Publishing: 29]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
16.  Lynch HT, Grady W, Lynch JF, Tsuchiya KD, Wiesner G, Markowitz SD. E-cadherin mutation-based genetic counseling and hereditary diffuse gastric carcinoma. Cancer Genet Cytogenet. 2000;122:1-6.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 17]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
17.  Fukudome Y, Yanagihara K, Takeichi M, Ito F, Shibamoto S. Characterization of a mutant E-cadherin protein encoded by a mutant gene frequently seen in diffuse-type human gastric carcinoma. Int J Cancer. 2000;88:579-583.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 6]  [Reference Citation Analysis (0)]
18.  Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, Sugimachi K. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 2000;128:408-416.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 91]  [Cited by in F6Publishing: 104]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
19.  Koseki K, Takizawa T, Koike M, Ito M, Nihei Z, Sugihara K. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression. Cancer. 2000;89:724-732.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 4]  [Reference Citation Analysis (0)]
20.  Uchiyama K, Yamamoto Y, Taniuchi K, Matsui C, Fushida Y, Shirao Y. Remission of antiepiligrin (laminin-5) cicatricial pemphigoid after excision of gastric carcinoma. Cornea. 2000;19:564-566.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 17]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
21.  Machado J, Carneiro F, Sobrinho-Simões M. E-cadherin mutations in gastric carcinoma. J Pathol. 2000;191:466-468.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 2]  [Reference Citation Analysis (0)]
22.  Chen J, Zhang Y, Chu Y. [Inhibition of human stomach cancer metastasis in vivo by anti-P-selectin monoclonal antibody]. Zhonghua Yixue Zazhi. 1998;78:437-439.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Luber B, Candidus S, Handschuh G, Mentele E, Hutzler P, Feller S, Voss J, Höfler H, Becker KF. Tumor-derived mutated E-cadherin influences beta-catenin localization and increases susceptibility to actin cytoskeletal changes induced by pervanadate. Cell Adhes Commun. 2000;7:391-408.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 29]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
24.  Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst. 2000;92:569-573.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 254]  [Cited by in F6Publishing: 253]  [Article Influence: 10.5]  [Reference Citation Analysis (0)]
25.  Höfler H. [Diffuse stomach carcinoma: from H& amp; E diagnosis and molecular pathology to specific therapy]. Verh Dtsch Ges Pathol. 1999;83:148-154.  [PubMed]  [DOI]  [Cited in This Article: ]
26.  Debruyne P, Vermeulen S, Mareel M. The role of the E-cadherin/catenin complex in gastrointestinal cancer. Acta Gastroenterol Belg. 1999;62:393-402.  [PubMed]  [DOI]  [Cited in This Article: ]
27.  Park CK, Shin YK, Kim TJ, Park SH, Ahn GH. High CD99 expression in memory T and B cells in reactive lymph nodes. J Korean Med Sci. 1999;14:600-606.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 25]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
28.  Stachura J, Krzeszowiak A, Popiela T, Urbańczyk K, Pituch-Noworolska A, Wieckiewicz J, Zembala M. Preferential overexpression of CD44v5 in advanced gastric carcinoma Goseki grades I and III. Pol J Pathol. 1999;50:155-161.  [PubMed]  [DOI]  [Cited in This Article: ]
29.  Chen JL, Wu YL. Selectins and tumor metastasis. Tumor. 1996;16:43-44.  [PubMed]  [DOI]  [Cited in This Article: ]
30.  Chen JL, Wu YL, Zhou T, Wang RN. Expression of P-selectin in human gastric cancer. Shanghai Dier Yike Daxue Xuebao. 1996;16:328-332.  [PubMed]  [DOI]  [Cited in This Article: ]
31.  Chen JL, Wu YL, Zhou T, Wang RN, Chu YD, Xu HM. Prognostic siginificance of P-selectin expression in Chinese patients with gastric carcinoma. J SMMU. 1999;11:66-70.  [PubMed]  [DOI]  [Cited in This Article: ]
32.  Chen JL, Zhang YX, Chu YD, Zhon T, Xu HM, Li ML. Inhibition of human stomach carcinoma metastasis in vivo by anti-P-selectin monoclonal antibody. Shanghai Dier Yike Daxue Xuebao. 1998;18:30-32.  [PubMed]  [DOI]  [Cited in This Article: ]
33.  Chen JL, Chu YD, Zhang YX, Xu HM, Li ML. Metastatic models of human gastric carcinoma established by orthotopic implantation of histologically intact specimens in SCID mice. Shanghai Shiyan Dongwu Kexue. 1997;17:207-209.  [PubMed]  [DOI]  [Cited in This Article: ]
34.  Koshikawa N, Moriyama K, Takamura H, Mizushima H, Nagashima Y, Yanoma S, Miyazaki K. Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. Cancer Res. 1999;59:5596-5601.  [PubMed]  [DOI]  [Cited in This Article: ]
35.  Becker KF, Kremmer E, Eulitz M, Becker I, Handschuh G, Schuhmacher C, Müller W, Gabbert HE, Ochiai A, Hirohashi S. Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody. Am J Pathol. 1999;155:1803-1809.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 57]  [Cited by in F6Publishing: 61]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
36.  Jawhari AU, Noda M, Pignatelli M, Farthing M. Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120(ctn) in gastric carcinoma. J Pathol. 1999;189:180-185.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 1]  [Reference Citation Analysis (0)]
37.  Nollet F, Berx G, van Roy F. The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun. 1999;2:77-85.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 144]  [Cited by in F6Publishing: 142]  [Article Influence: 5.7]  [Reference Citation Analysis (0)]
38.  Schuhmacher C, Becker KF, Reich U, Schenk U, Mueller J, Siewert JR, Höfler H. Rapid detection of mutated E-cadherin in peritoneal lavage specimens from patients with diffuse-type gastric carcinoma. Diagn Mol Pathol. 1999;8:66-70.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 16]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
39.  Hsieh HF, Yu JC, Ho LI, Chiu SC, Harn HJ. Molecular studies into the role of CD44 variants in metastasis in gastric cancer. Mol Pathol. 1999;52:25-28.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 32]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
40.  Jawhari AU, Noda M, Farthing MJ, Pignatelli M. Abnormal expression and function of the E-cadherin-catenin complex in gastric carcinoma cell lines. Br J Cancer. 1999;80:322-330.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 36]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
41.  Sato S, Yokozaki H, Yasui W, Nikai H, Tahara E. Silencing of the CD44 gene by CpG methylation in a human gastric carcinoma cell line. Jpn J Cancer Res. 1999;90:485-489.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 21]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
42.  Yoo CH, Noh SH, Kim H, Lee HY, Min JS. Prognostic significance of CD44 and nm23 expression in patients with stage II and stage IIIA gastric carcinoma. J Surg Oncol. 1999;71:22-28.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 3]  [Reference Citation Analysis (0)]
43.  Nakanishi H, Kodera Y, Yamamura Y, Kuzuya K, Nakanishi T, Ezaki T, Tatematsu M. Molecular diagnostic detection of free cancer cells in the peritoneal cavity of patients with gastrointestinal and gynecologic malignancies. Cancer Chemother Pharmacol. 1999;43 Suppl:S32-S36.  [PubMed]  [DOI]  [Cited in This Article: ]
44.  Taniuchi K, Takata M, Matsui C, Fushida Y, Uchiyama K, Mori T, Kawara S, Yancey KB, Takehara K. Antiepiligrin (laminin 5) cicatricial pemphigoid associated with an underlying gastric carcinoma producing laminin 5. Br J Dermatol. 1999;140:696-700.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 30]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
45.  Koyama S, Maruyama T, Adachi S. Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis. J Cancer Res Clin Oncol. 1999;125:47-54.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 28]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
46.  Isozaki H, Ohyama T, Mabuchi H. Expression of cell adhesion molecule CD44 and sialyl Lewis A in gastric carcinoma and colorectal carcinoma in association with hepatic metastasis. Int J Oncol. 1998;13:935-942.  [PubMed]  [DOI]  [Cited in This Article: ]
47.  Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer. 1998;83:1094-1101.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 3]  [Reference Citation Analysis (0)]
48.  Harn HJ, Shen KL, Liu CA, Ho LI, Yang LS, Yueh KC. Hyaluronate binding assay study of transfected CD44 V4-V7 isoforms into the human gastric carcinoma cell line SC-M1. J Pathol. 1998;184:291-296.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 1]  [Reference Citation Analysis (0)]
49.  Yasui W, Kudo Y, Naka K, Fujimoto J, Ue T, Yokozaki H, Tahara E. Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression. Int J Oncol. 1998;12:1253-1258.  [PubMed]  [DOI]  [Cited in This Article: ]
50.  Castellà EM, Ariza A, Pellicer I, Fernández-Vasalo A, Ojanguren I. Differential expression of CD44v6 in metastases of intestinal and diffuse types of gastric carcinoma. J Clin Pathol. 1998;51:134-137.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 22]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
51.  Chen JL, Zhou T, Chu YD, Xu HM, Li X, Zhang MJ, Zhang DH, Wu YL. The significance of intercellular adhesion molecule-1 and P-selectin in hepatic ischemia-reperfusion injury. Zhongguo Weizhongbing Jijiuyixue. 1998;10:670-672.  [PubMed]  [DOI]  [Cited in This Article: ]
52.  Chen JL, Chu YD, Zhou T, Xu HM, Li X, Zhang MJ. Effects of P-selectin and anti-P-selectin antibody on apoptosis during liver ischemia-reperfusion injury. Shanghai Dier Yike Daxue Xuebao. 2000;20:239-241.  [PubMed]  [DOI]  [Cited in This Article: ]
53.  Wu P, Li X, Zhou T, Zhang MJ, Chen JL, Wang WM, Chen N, Dong DC. Role of P-selectin and anti-P-selectin monoclonal antibody in apoptosis during hepatic/renal ischemia reperfusion injury. World J Gastroenterol. 2000;6:244-247.  [PubMed]  [DOI]  [Cited in This Article: ]
54.  Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 228]  [Cited by in F6Publishing: 235]  [Article Influence: 10.7]  [Reference Citation Analysis (1)]
55.  Berdichevsky Y, Zemel R, Bachmatov L, Abramovich A, Koren R, Sathiyamoorthy P, Golan-Goldhirsh A, Tur-Kaspa R, Benhar I. A novel high throughput screening assay for HCV NS3 serine protease inhibitors. J Virol Methods. 2003;107:245-255.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 26]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]